9 Participants Needed

Inclisiran for Hypercholesterolemia

(ORION-19 Trial)

Recruiting at 5 trial locations
NP
Overseen ByNovartis Pharmaceuticals
Age: < 18
Sex: Any
Trial Phase: Phase 3
Sponsor: Novartis Pharmaceuticals
Must be taking: Statins
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).

Will I have to stop taking my current medications?

No, you won't have to stop your current medications. Participants must stay on a stable dose of their lipid-lowering therapies, like statins or ezetimibe, for at least 30 days before the trial and continue without changes during the study.

What data supports the effectiveness of the drug Inclisiran for treating hypercholesterolemia?

Research shows that Inclisiran effectively lowers LDL cholesterol (a type of bad cholesterol) by about 50% in patients with high cholesterol, even when they are already on other cholesterol-lowering medications. It also helps reduce the risk of heart-related events and is safe and well-tolerated.12345

Is Inclisiran safe for humans?

Inclisiran has been tested in several clinical trials, and no severe adverse effects or safety concerns directly related to the drug have been reported. It is considered safe and well-tolerated for lowering cholesterol levels.23678

How does the drug inclisiran differ from other treatments for hypercholesterolemia?

Inclisiran is unique because it is a small interfering RNA drug that lowers cholesterol by blocking the production of a protein called PCSK9, which helps reduce bad cholesterol (LDL-C). Unlike other treatments, it is administered only twice a year, making it easier for patients to stick to their treatment plan.3491011

Research Team

NP

Novartis Pharmaceuticals

Principal Investigator

Novartis Pharmaceuticals

Eligibility Criteria

This trial is for children aged 2 to less than 12 with homozygous familial hypercholesterolemia (HoFH), a genetic condition causing very high cholesterol. Participants must have genetically confirmed HoFH but can't join if they have certain mutations in both LDLR alleles.

Inclusion Criteria

I am between 2 and 11 years old.
My HoFH diagnosis was confirmed through genetic testing.
I do not have negative mutations in both LDLR genes.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment (Year 1)

Participants receive either inclisiran or placebo subcutaneous injections at Days 1, 90, and 270

12 months
3 visits (in-person)

Open-label Treatment (Year 2)

All participants receive inclisiran subcutaneous injections at Days 360, 450, and 630

12 months
3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Inclisiran
Trial OverviewThe study tests the safety and effectiveness of Inclisiran, a medication aimed at lowering cholesterol levels, compared to a placebo. It's designed for young patients with severe inherited high cholesterol.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: InclisiranExperimental Treatment1 Intervention
Year 1 - inclisiran sodium subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium subcutaneous injection (given at Days 450 and 630)
Group II: PlaceboPlacebo Group1 Intervention
Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium subcutaneous injection (given at Days 360, 450, and 630)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Novartis Pharmaceuticals

Lead Sponsor

Trials
2,963
Recruited
4,275,000+
Founded
1996
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Gleevec, Cosentyx, Entresto, Kisqali
Dr. Vas Narasimhan profile image

Dr. Vas Narasimhan

Novartis Pharmaceuticals

Chief Executive Officer since 2018

MD from Harvard Medical School

Dr. Shreeram Aradhye profile image

Dr. Shreeram Aradhye

Novartis Pharmaceuticals

Chief Medical Officer since 2021

MD

Findings from Research

Inclisiran significantly reduces low-density lipoprotein cholesterol (LDLc) levels, with an average reduction of 60.6 mg/dl, based on a meta-analysis of 57,431 patients, including 1,592 treated with Inclisiran.
The treatment with Inclisiran is associated with a reduction in major cardiovascular events (MACE), aligning with findings from trials involving other PCSK9 inhibitors, suggesting its potential effectiveness in preventing cardiovascular issues.
Estimation of the major cardiovascular events prevention with Inclisiran.Cordero, A., Santos-Gallego, CG., Fácila, L., et al.[2022]
Inclisiran, a novel treatment for lowering LDL cholesterol, was evaluated in two phase 3 trials involving a significant number of patients, demonstrating its efficacy in reducing LDL levels over time.
The results indicated that inclisiran effectively lowered LDL cholesterol levels compared to placebo, suggesting it could be a valuable option for patients struggling with high cholesterol.
In patients with ASCVD and elevated LDL-C with maximal statin therapy, inclisiran reduced LDL-C levels at 18 months.Clark, J., Montori, V.[2020]
Inclisiran is an effective treatment for dyslipidemia, significantly lowering LDL cholesterol (LDL-C) levels through a novel mechanism that silences the PCSK9 gene, as demonstrated in clinical trials from the ORION program.
The safety profile of inclisiran is favorable, with adverse events similar to placebo, although injection-site reactions were more common; this suggests it is a well-tolerated option for patients compared to other PCSK9 therapies.
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.Banerjee, Y., Pantea Stoian, A., Cicero, AFG., et al.[2022]

References

Estimation of the major cardiovascular events prevention with Inclisiran. [2022]
In patients with ASCVD and elevated LDL-C with maximal statin therapy, inclisiran reduced LDL-C levels at 18 months. [2020]
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. [2022]
Inclisiran for the Treatment of Hyperlipidemia and for Atherosclerotic Cardiovascular Disease Risk Reduction: A Narrative Review. [2023]
Clinical implications and outcomes of the ORION Phase III trials. [2022]
Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists. [2021]
Serious adverse events of Inclisiran in patients with hypercholesterolemia, a meta analysis of ORION trials. [2023]
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. [2023]
Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis. [2023]
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. [2020]
Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. [2022]